Spots Global Cancer Trial Database for A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
Official Title: A Phase 2, Multicenter, Non-Randomized, Open-Label, Single-Arm Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Relapsed or Refractory Lymphoma
Study ID: NCT05446688
Conditions
Interventions
Study Description
Brief Summary: This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Saijuan Chen, Doctor
Affiliation: Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Name: Weili Zhao, Doctor
Affiliation: Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
